Pro-Dex Hits 10th Straight Year of Sales Growth, Eyes FY26 Expansion

TL;DR

**PDEX is a buy; 10 years of sales growth and a strong backlog signal continued upside, despite standard governance votes.**

AI Summary

PRO-DEX, INC. (PDEX) reported its tenth consecutive year of sales growth in Fiscal 2025, achieving $65 million in sales, a 24% increase year-over-year. The company focused on assisting customers with major product launches, strengthening its management team, and enhancing manufacturing systems. Looking ahead to Fiscal 2026, Pro-Dex anticipates continued growth driven by a healthy backlog, new customer acquisitions, and ongoing product and technology development. The DEF 14A filing outlines key proposals for the upcoming Annual Meeting on November 20, 2025, including the election of seven directors, ratification of Baker Tilly US, LLP as the independent auditor for fiscal year ending June 30, 2026, an advisory vote on executive compensation, and a proposal to extend the 2016 Equity Incentive Compensation Plan for an additional ten years. Shareholder voting is crucial for these strategic decisions, with the Board recommending 'for' all proposals except for a '1 Year' frequency for future executive compensation votes. As of September 23, 2025, 3,280,004 shares of Common Stock were outstanding, with significant beneficial ownership held by Nicholas J. Swenson (31.2%) and Raymond E. Cabillot (8.4%).

Why It Matters

This DEF 14A filing signals PRO-DEX's continued growth trajectory, with a 24% sales increase to $65 million in Fiscal 2025, which is a strong indicator for investors seeking consistent performance in the medical device and industrial technology sectors. The proposed extension of the 2016 Equity Incentive Compensation Plan could impact employee retention and motivation, directly affecting the company's ability to innovate and compete. For customers, the focus on new product development and improved manufacturing systems suggests a commitment to enhanced offerings and reliability, potentially strengthening PRO-DEX's competitive position against rivals like Integer Holdings or Nordson Corporation. The election of directors and ratification of auditors are standard governance items, but the advisory vote on executive compensation provides shareholders a voice on leadership incentives, influencing long-term strategic alignment.

Risk Assessment

Risk Level: low — The filing indicates a low risk level due to the company's consistent financial performance, specifically its tenth consecutive year of sales growth, achieving $65 million in Fiscal 2025. The healthy backlog and new product development mentioned by CEO Rick Van Kirk suggest strong future revenue visibility, mitigating immediate operational risks.

Analyst Insight

Investors should vote 'FOR' the extension of the 2016 Equity Incentive Compensation Plan to align executive incentives with long-term shareholder value. Given the strong sales growth and positive outlook, consider increasing exposure to PDEX, as the company appears well-positioned for continued expansion.

Financial Highlights

revenue

$65M

revenue Growth

+24%

Executive Compensation

Key Numbers

• $65M — Fiscal 2025 Sales (Represents a 24% year-over-year growth and tenth consecutive year of sales growth for Pro-Dex.)
• 24% — Year-over-year sales growth (Indicates the growth rate of Pro-Dex's sales in Fiscal 2025.)
• 2025-11-20 — Annual Meeting Date (Date for the Annual Meeting of Shareholders to vote on key proposals.)
• 3,280,004 — Shares of Common Stock outstanding (Total shares entitled to vote as of the September 23, 2025 record date.)
• 31.2% — Beneficial ownership by Nicholas J. Swenson (Represents a significant stake held by the Chairman of the Board.)
• 8.4% — Beneficial ownership by Raymond E. Cabillot (Represents a notable stake held by a director.)
• 10 — Years of sales growth (Indicates the company's consistent growth trend.)

Key Players & Entities

• PRO-DEX, INC. (company) — Registrant and company filing DEF 14A
• Rick Van Kirk (person) — President and Chief Executive Officer of Pro-Dex
• Baker Tilly US, LLP (company) — Independent registered public accounting firm nominee
• Nicholas J. Swenson (person) — Director, Chairman of the Board, and significant beneficial owner (31.2%)
• Raymond E. Cabillot (person) — Director and significant beneficial owner (8.4%)
• Alisha K. Charlton (person) — Corporate Secretary of Pro-Dex
• Angelita R. Domingo (person) — Director and Director of Quality Systems and Regulatory Affairs at Pro-Dex
• William J. Farrell III (person) — Director and Chief Strategy & Innovation Officer of Emplify Health
• David C. Hovda (person) — Director
• Katrina M.K. Philp (person) — Director

FAQ

Industry Context

Pro-Dex operates in the medical device component manufacturing sector, which is characterized by stringent quality requirements and long-standing customer relationships. The industry is driven by innovation in medical technologies and the need for reliable, high-precision manufacturing partners. Companies like Pro-Dex often benefit from the increasing demand for minimally invasive surgical devices and advanced diagnostic equipment.

Regulatory Implications

As a public company, Pro-Dex is subject to SEC regulations governing proxy solicitations and corporate governance. The company must ensure compliance with rules regarding shareholder voting, disclosure of executive compensation, and the ratification of independent auditors. Any missteps in these areas could lead to regulatory scrutiny and potential penalties.

What Investors Should Do

1. Vote on all proposals at the Annual Meeting.
2. Review the Board's recommendations for each proposal.
3. Consider the company's consistent sales growth and future outlook.

Key Dates

• 2025-11-20: Annual Meeting of Shareholders — Shareholders will vote on key proposals including director elections, auditor ratification, executive compensation, and equity plan extension.
• 2025-09-23: Record Date for Annual Meeting — Establishes the shareholders eligible to vote at the Annual Meeting.
• 2026-06-30: Fiscal Year End — The independent auditor is being ratified for this fiscal year.
• 2025-10-10: Mailing of Proxy Materials — Shareholders receive notice and access to proxy materials for the Annual Meeting.

Glossary

DEF 14A

A filing with the SEC that provides detailed information to shareholders about matters to be voted on at an annual meeting. (This document outlines the proposals and information shareholders need to consider for the Pro-Dex, Inc. annual meeting.)

Proxy Statement

A document that a company must provide to shareholders before soliciting their votes for a corporate matter. (This is the core document for the annual meeting, detailing the proposals and board recommendations.)

Named Executive Officers (NEOs)

The top executive officers of a company whose compensation is disclosed in proxy statements. (Shareholders will vote on the compensation of Pro-Dex's NEOs.)

Equity Incentive Compensation Plan

A plan that allows a company to grant stock options, restricted stock, or other equity-based awards to employees and directors. (Pro-Dex is seeking to extend its 2016 Equity Incentive Compensation Plan for another ten years.)

Independent Registered Public Accounting Firm

An external audit firm hired by a company to conduct an independent audit of its financial statements. (Shareholders are asked to ratify the appointment of Baker Tilly US, LLP for the fiscal year ending June 30, 2026.)

Beneficial Ownership

The power to direct the voting or disposition of securities, even if not the legal owner. (The filing details significant beneficial ownership by key individuals like Nicholas J. Swenson and Raymond E. Cabillot.)

Year-Over-Year Comparison

The DEF 14A filing highlights Pro-Dex's tenth consecutive year of sales growth, reaching $65 million in Fiscal 2025, a significant 24% increase year-over-year. This contrasts with previous filings that would have shown a lower sales figure and growth rate for Fiscal 2024. The current filing also focuses on proposals for the upcoming annual meeting, including extending the equity incentive plan, which may or may not have been a prominent feature in prior year filings. No new material risks or significant changes in financial structure are detailed in this proxy statement compared to the previous year's reporting, but the continued strong performance is a key theme.

Key Financial Figures

• $65M — 24% year-over-year growth finishing at $65M in sales. Other highlights include assi

Filing Documents

• pdex_def14a.htm (DEF 14A) — 535KB
• logo.jpg (GRAPHIC) — 8KB
• image_001.jpg (GRAPHIC) — 26KB
• image_001.gif (GRAPHIC) — 11KB
• image_002.jpg (GRAPHIC) — 81KB
• image_003.jpg (GRAPHIC) — 57KB
• 0001079973-25-001567.txt ( ) — 1601KB
• pdex-20250630.xsd (EX-101.SCH) — 6KB
• pdex-20250630_def.xml (EX-101.DEF) — 10KB
• pdex-20250630_lab.xml (EX-101.LAB) — 59KB
• pdex-20250630_pre.xml (EX-101.PRE) — 43KB
• pdex_def14a_htm.xml (XML) — 133KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information concerning the beneficial ownership of our Common Stock as of September 23, 2025 by: each member of the Board; each of our Named Executive Officers listed in the "Summary Compensation Table" included in the "Executive Compensation" section of this proxy statement; all of our directors and Named Executive Officers as a group; and each person or entity known to us that beneficially owns more than five percent of our Common Stock. Beneficial ownership is determined in accordance with the rules of the SEC. Unless otherwise indicated below, the address of each beneficial owner is c/o Pro-Dex, Inc., 2361 McGaw Avenue, Irvine, California, 92614. Unless otherwise indicated below, we believe that each of the persons listed in the table (subject to applicable community property laws) has the sole power to vote and to dispose of the shares listed opposite the shareholder's name. The percentages of Common Stock beneficially owned are based on 3,280,004 shares of Common Stock outstanding at September 23, 2025. Name and Address of Beneficial Owner Number of Shares of Common Stock Beneficially Owned Percent of Common Stock Beneficially Owned (1) Nicholas J. Swenson, AO Partners I, L.P.; and AO Partners, LLC; (2), (4) 5000 West 36 th Street, Suite 200 Minneapolis, MN 55416 1,024,017 31.2 % Raymond E. Cabillot; Farnam Street Partners, L.P.; Farnam Street Capital, Inc.; and Peter O. Haeg (3), (4) 3033 Excelsior Blvd., Suite 560 Minneapolis, MN 55416 277,046 8.4 % Richard L. Van Kirk (4) 125,979 3.8 % Alisha K. Charlton (4) 22,414 * Katrina M.K. Philp (4), (5) 20,896 * Angelita R. Domingo (4) 15,844 * William J. Farrell III (4) 11,300 * David C. Hovda (4) 8,400 * All Directors, Director Nominees and Named Executive Officers as a group (8 persons) (4) 1,505,896 45.9 % ____________ * Indicates less than 1 percent of

View Full Filing

View this DEF 14A filing on SEC EDGAR